Sign In
Buy AXNX
$70.98
+0 (+0%)
At Close: Feb 13, 2025
Axonics® Announces Upsize and Pricing of Public Offering of Common Stock
10:55pm, Tuesday, 11'th May 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder
Axonics® Announces Proposed Public Offering of Common Stock
04:17pm, Tuesday, 11'th May 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics' (AXNX) CEO Raymond Cohen on Q1 2021 Results - Earnings Call Transcript
12:07pm, Sunday, 09'th May 2021
Axonics' (AXNX) CEO Raymond Cohen on Q1 2021 Results - Earnings Call Transcript
Axonics® to Participate in the BofA Securities 2021 Virtual Healthcare Conference
06:00am, Thursday, 22'nd Apr 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfu
Axonics® to Report First Quarter 2021 Financial Results on May 6, 2021
06:00am, Thursday, 15'th Apr 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfu
Axonics® to Participate in the Barclays Global Healthcare Conference
06:00am, Wednesday, 03'rd Mar 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of
Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device
06:00am, Tuesday, 02'nd Mar 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of
Axonics Modulation Technologies' (AXNX) CEO Raymond Cohen on Q4 2020 Results - Earnings Call Transcript
07:50am, Saturday, 27'th Feb 2021
Axonics Modulation Technologies' (AXNX) CEO Raymond Cohen on Q4 2020 Results - Earnings Call Transcript
Axonics Acquires Urethral Bulking Agent For $200M
08:37am, Friday, 26'th Feb 2021
Axonics Modulation Technologies Inc (NASDAQ: AXNX) has acquired UK-based Contura and its lead product Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence. The trans
Axonics Modulation Tech Earnings Preview
10:07am, Wednesday, 24'th Feb 2021
On Thursday, February 25, Axonics Modulation Tech (NASDAQ:AXNX) will release its latest earnings report. Benzinga's outlook for Axonics Modulation Tech is included in the following report.
Axonics® to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 25, 2021
04:01pm, Monday, 22'nd Feb 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (
Axonics® to Participate in the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2021 Winter Meeting
06:00am, Thursday, 18'th Feb 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (
Axonics® Receives FDA Approval for Third-Generation Implantable Neurostimulator
06:00am, Tuesday, 16'th Feb 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (
Axonics® to Participate in the SVB Leerink Global Healthcare Conference
06:00am, Thursday, 11'th Feb 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2020 Revenue
04:01pm, Monday, 25'th Jan 2021
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (
